Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02126579 · ClinicalTrials.gov registry record · Phase 1
Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists
A Phase 1 study of Melanoma and Metastatic Melanoma, sponsored by Craig L Slingluff, Jr.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 2
- Study locations
NCT02126579: Completed Phase 1 study of Melanoma and Metastatic Melanoma, sponsored by Craig L Slingluff, Jr.
NCT02126579 is a Phase 1 study of Melanoma and Metastatic Melanoma that has completed, run by Craig L Slingluff, Jr. The registered enrollment target is 50 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (93% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02126579, a Phase 1 study of Melanoma and Metastatic Melanoma, has completed, sponsored by Craig L Slingluff, Jr.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to learn what effects (good and bad) an experimental vaccine (LPV7) plus tetanus peptide and other substances called polyICLC, resiquimod, and Montanide ISA-51 have on you and your melanoma. We will also look at whether the experimental vaccine and these drugs cause any changes in your immune system.
Primary Outcome
Safety and toxicity following vaccination with 7 long peptides in melanoma patients with and without TLR agonists. Patients are evaluated by safety labs and physical exams to assess for toxicity.
Conditions Studied
Interventions
- BIOLOGICAL Peptide Vaccine (LPV7) + Tetanus peptide
- OTHER PolyICLC
- OTHER Resiquimod
- OTHER IFA
Study Locations (2)
Texas
- MDAnderson Cancer Center - Houston
Virginia
- University of Virginia - Charlottesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-05-01 |
| Est. Completion | 2021-05-05 |
| Phase | Phase 1 |
What the finished NCT02126579 record still lists
NCT02126579 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (93% lower).
The record links to 3 conditions, with Melanoma appearing as the primary indexed condition, and to 4 interventions - of which Peptide Vaccine (LPV7) + Tetanus peptide is the first listed.
NCT02126579 reports a single indexed study location in Texas, Virginia.
Frequently Asked Questions
What is clinical trial NCT02126579 about?
NCT02126579 is a clinical study titled "Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists". The purpose of this study is to learn what effects (good and bad) an experimental vaccine (LPV7) plus tetanus peptide and other substances called polyICLC, resiquimod, and Montanide ISA-51 have on you and your melanoma. We will also look at whether the experimental vaccine and these drugs cause any ...
What is the current status of trial NCT02126579?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2014-05-01. Estimated completion is 2021-05-05.
What conditions does trial NCT02126579 study?
This clinical trial studies the following conditions: Melanoma, Metastatic Melanoma, Mucosal Melanoma.
What interventions are being tested in trial NCT02126579?
The interventions under investigation include: Peptide Vaccine (LPV7) + Tetanus peptide (BIOLOGICAL), PolyICLC (OTHER), Resiquimod (OTHER), IFA (OTHER).
Who is sponsoring clinical trial NCT02126579?
This trial is sponsored by Craig L Slingluff, Jr, which has 23 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02126579 being conducted?
This trial has 2 study locations across Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02126579's enrollment target sits among peer trials
50 163rd of 266 higher than 99 of 266 other Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
-
Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI